Inmune Bio (INMB) Consolidated Net Income (2018 - 2025)
Historic Consolidated Net Income for Inmune Bio (INMB) over the last 7 years, with Q3 2025 value amounting to -$7.4 million.
- Inmune Bio's Consolidated Net Income rose 3950.02% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$51.4 million, marking a year-over-year decrease of 2365.75%. This contributed to the annual value of -$42.6 million for FY2024, which is 4207.88% down from last year.
- As of Q3 2025, Inmune Bio's Consolidated Net Income stood at -$7.4 million, which was up 3950.02% from -$24.6 million recorded in Q2 2025.
- Over the past 5 years, Inmune Bio's Consolidated Net Income peaked at -$4.5 million during Q1 2021, and registered a low of -$24.6 million during Q2 2025.
- Over the past 5 years, Inmune Bio's median Consolidated Net Income value was -$8.4 million (recorded in 2023), while the average stood at -$8.9 million.
- Examining YoY changes over the last 5 years, Inmune Bio's Consolidated Net Income showed a top increase of 3950.02% in 2025 and a maximum decrease of 14907.25% in 2025.
- Over the past 5 years, Inmune Bio's Consolidated Net Income (Quarter) stood at -$9.0 million in 2021, then soared by 37.52% to -$5.6 million in 2022, then tumbled by 48.51% to -$8.4 million in 2023, then fell by 12.98% to -$9.5 million in 2024, then grew by 21.49% to -$7.4 million in 2025.
- Its last three reported values are -$7.4 million in Q3 2025, -$24.6 million for Q2 2025, and -$9.9 million during Q1 2025.